The President of the Egypt Healthcare Authority met with the Regional President of Novartis for the Middle East and Africa to discuss the roadmap for cooperation between the two sides in the upcoming phase.
The President of the Egypt Healthcare Authority stated that they have a strategic partnership with Novartis, which has yielded successes on several levels, notably in raising awareness and treating heart diseases, as well as in building and developing the capabilities of human resources in the governorates where the first phase of universal health insurance is being implemented.
The President of the Healthcare Authority mentioned that future cooperation with Novartis will include several areas, most importantly the establishment of centers of excellence for heart diseases, cancer treatment, and immunological diseases. It will also extend the scope of awareness and early disease detection, and leverage artificial intelligence for proactive disease diagnosis using data.
The President noted that there are over 6 million medical records in the governorates included in the first phase of universal health insurance. There is an aspiration to establish a national library for heart diseases, cancer, immune diseases, and rare diseases.
He highlighted the availability of scientific guidelines, updated and innovative treatments, and the rational use of medications, as well as measuring the efficiency, effectiveness, and safety of medications as part of the collaboration between the Authority and Novartis.
The CEO of Novartis for Africa and the Middle East expressed appreciation for the cooperation with the Egypt Healthcare Authority and acknowledged its role in providing comprehensive healthcare under the umbrella of universal health coverage with the highest standards of quality. He praised their ongoing commitment to enhancing the expertise of family doctors.
The CEO of Novartis noted real results in improving health indicators and patient satisfaction rates through all joint initiatives with the Egypt Healthcare Authority, which motivates them for further cooperation in the upcoming period.
The Novartis delegation expressed their satisfaction with the rapid achievements in health reform in Egypt, including the quality of facilities, healthcare quality, and the implementation of global standards, which includes environmental, financial, and institutional sustainability.
The delegation included Tracy Goodridge, CEO of Novartis for Africa and the Middle East; Jaideep Gadgil, CFO for Novartis Asia, Africa, and the Middle East; Gilbert Verkuijlen, Regional Director for Medicine Provision and Market Support for Novartis in Asia, Africa, and the Middle East; Esther Eng, Regional Director for Medicine Provision for Novartis in Africa and the Middle East; Yo Shimizu, CFO for Novartis Africa and the Middle East; Angela Yang, CFO for Novartis Egypt; Dr. Mohamed Sabry, Director of Medicine Provision and Market Support for Novartis Egypt; Amro Amin, Director of Public Relations for Novartis Egypt; and Abdel Aziz Ahmed, Manager of Medicine Provision and Market Support for Cardiovascular Diseases at Novartis Egypt.
They were received by a number of leaders from the Egypt Healthcare Authority, including Dr. Ahmed Hammad, Advisor to the President of the Authority for Health Policies and Systems; Dr. Sherif Kamal, Advisor to the President for Pharmacy and Medicinal Affairs; Dr. Sally Abdelraouf, Head of the Central Administration for Healthcare and Treatment; Dr. Radwa Imam, Director of Health Education and Initiatives; Dr. Heba Awaida, Director of Training and Development; Dr. Asmaa Salman, Director of Marketing and Business Development; and Dr. Radwa Abdel Azim, a member of the President's Technical Office.
